This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neyts, J.
Right arrow Articles by De Clercq, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neyts, J.
Right arrow Articles by De Clercq, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1999, p. 2885-2892, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Hydroxyurea Potentiates the Antiherpesvirus Activities of Purine and Pyrimidine Nucleoside and Nucleoside Phosphonate Analogs

J. Neyts* and E. De Clercq

Rega Institute for Medical Research, K. U. Leuven, B-3000 Leuven, Belgium

Received 24 March 1999/Returned for modification 16 June 1999/Accepted 20 September 1999

Hydroxyurea has been shown to potentiate the anti-human immunodeficiency virus activities of 2',3'-dideoxynucleoside analogs such as didanosine. We have now evaluated in vitro the effect of hydroxyurea on the antiherpesvirus activities of several nucleoside analogs (acyclovir [ACV], ganciclovir [GCV], penciclovir [PCV], lobucavir [LBV], (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine [H2G], and brivudin and nucleoside phosphonate analogs (cidofovir [CDV] and adefovir [ADV]). When evaluated in cytopathic effect (CPE) reduction assays, hydroxyurea by itself had little effect on CPE progression and potentiated in a subsynergistic (herpes simplex virus type 1 [HSV-1]) to synergistic (HSV-2) fashion the antiviral activities of ACV, GCV, PCV, LBV, H2G, ADV, and CDV. Hydroxyurea also caused marked increases in the activities of ACV, GCV, PCV, LBV, and H2G (compounds that depend for their activation on a virus-encoded thymidine kinase [TK]) against TK-deficient (TK-) HSV-1. In fact, in combination with hydroxyurea the 50% effective concentrations of these compounds for inhibition of TK- HSV-1-induced CPE decreased from values of 20 to >= 100 µg/ml (in the absence of hydroxyurea) to values of 1 to 5 µg/ml (in the presence of hydroxyurea at 25 to 100 µg/ml). When evaluated in a single-cycle virus yield reduction assay, hydroxyurea at a concentration of 100 µg/ml inhibited progeny virus production by 60 to 90% but had little effect on virus yield at a concentration of 25 µg/ml. Under these assay conditions hydroxyurea still elicited a marked potentiating effect on the antiherpesvirus activities of GCV and CDV, but this effect was less pronounced than that in the CPE reduction assay. It is conceivable that the potentiating effect of hydroxyurea stems from a depletion of the intracellular deoxynucleoside triphosphate pools, thus favoring the triphosphates of the nucleoside analogues (or the diphosphates of the nucleoside phosphonate analogues) in their competition with the natural nucleotides at the viral DNA polymerase level. The possible clinical implications of these findings are discussed.


* Corresponding author. Mailing address: Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Phone: (32)-16-33.73.53. Fax: (32)-16-33.73.40. E-mail: johan.neyts{at}rega.kuleuven.ac.be.


Antimicrobial Agents and Chemotherapy, December 1999, p. 2885-2892, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Mattiuzzi, G. N., Cortes, J. E., Talpaz, M., Reuben, J., Rios, M. B., Shan, J., Kontoyiannis, D., Giles, F. J., Raad, I., Verstovsek, S., Ferrajoli, A., Kantarjian, H. M. (2003). Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate. Clin. Cancer Res. 9: 976-980 [Abstract] [Full Text]